Publications

Annals of oncology : official journal of the European Society for Medical Oncology

Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma.

01-06-2016

Urologic oncology

Baseline tumor volume in assessing prognosis of patients with intermediate-risk synchronous metastatic renal cell carcinoma.

01-06-2016

Science (New York, N.Y.)

CANCER IMMUNOLOGY. The "cancer immunogram".

06-05-2016

The Prostate

Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation.

01-01-2016

Journal of immunology (Baltimore, Md. : 1950)

Subtle CXCR3-Dependent Chemotaxis of CTLs within Infected Tissue Allows Efficient Target Localization.

01-12-2015

Molecular oncology

Tumor-infiltrating lymphocytes for the treatment of metastatic cancer.

01-12-2015

Clinical cancer research : an official journal of the American Association for Cancer Research

Translating Pembrolizumab to Clinical Practice: Speak Immunology and Learn Fast!

01-10-2015

Cancer immunology, immunotherapy : CII

Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma.

01-10-2015

Molecular therapy : the journal of the American Society of Gene Therapy

Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor.

01-09-2015

Ophthalmology

Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma.

01-09-2015

EMBO molecular medicine

Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts.

01-09-2015

Lancet (London, England)

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.

01-08-2015

Nature reviews. Cancer

Evolving synergistic combinations of targeted immunotherapies to combat cancer.

01-08-2015

The New England journal of medicine

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

02-07-2015

Gene therapy

Antigen design enhances the immunogenicity of Semliki Forest virus-based therapeutic human papillomavirus vaccines.

01-07-2015

British journal of cancer

Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.

30-06-2015

Seminars in oncology

Toxicity patterns with immunomodulating antibodies and their combinations.

01-06-2015

European journal of cancer (Oxford, England : 1990)

Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression.

01-03-2015

Journal of translational medicine

NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy.

27-01-2015

Nature medicine

High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma.

01-01-2015

Nature communications

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.

15-12-2014

Science (New York, N.Y.)

T cell memory. Skin-resident memory CD8⁺ T cells trigger a state of tissue-wide pathogen alert.

03-10-2014

Human gene therapy methods

Manufacture of gene-modified human T-cells with a memory stem/central memory phenotype.

01-10-2014

Science translational medicine

Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.

17-09-2014

Molecular oncology

Acquired and intrinsic resistance in cancer immunotherapy.

12-09-2014

Cancer immunology research

Immune-escape markers in relation to clinical outcome of advanced melanoma patients following immunotherapy.

01-06-2014

British journal of cancer

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.

13-05-2014

Cancer immunology, immunotherapy : CII

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.

01-05-2014

Methods in molecular biology (Clifton, N.J.)

Intradermal vaccination by DNA tattooing.

10-04-2014

Nature

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.

03-04-2014

The Lancet. Oncology

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.

01-03-2014

World journal of urology

Do targeted agents offer clinical benefit as presurgical therapy?

01-02-2014

BMC cancer

Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma.

01-12-2013

European journal of clinical pharmacology

The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand-foot syndrome.

01-12-2013

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma.

10-11-2013

Nature medicine

High-throughput identification of antigen-specific TCRs by TCR gene capture.

01-11-2013

Acta oncologica (Stockholm, Sweden)

Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O).

01-11-2013

Annals of oncology : official journal of the European Society for Medical Oncology

Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20).

01-10-2013

EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.]

Immunotherapy of melanoma.

01-09-2013

Vaccine

Transposon leads to contamination of clinical pDNA vaccine.

11-07-2013

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Vemurafenib as neoadjuvant treatment for unresectable regional metastatic melanoma.

01-06-2013

Cancer treatment reviews

Is combination therapy the next step to overcome resistance and reduce toxicities in melanoma?

01-06-2013

The Netherlands journal of medicine

Recent advances towards the clinical application of DNA vaccines.

01-04-2013

Human gene therapy

Rational design of DNA vaccines for the induction of human papillomavirus type 16 E6- and E7-specific cytotoxic T-cell responses.

01-12-2012

Proceedings of the National Academy of Sciences of the United States of America

Tissue-resident memory CD8+ T cells continuously patrol skin epithelia to quickly recognize local antigen.

27-11-2012

Oncoimmunology

TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients.

01-07-2012

Advances in immunology

Behavior and function of tissue-resident memory T cells.

28-03-2012

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission.

10-01-2012

Lancet (London, England)

Tilting the AXIS towards therapeutic limits in renal cancer.

03-12-2011

Nederlands tijdschrift voor geneeskunde

[Issues around melanoma].

17-11-2011

Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma.

Baseline tumor volume in assessing prognosis of patients with intermediate-risk synchronous metastatic renal cell carcinoma.

CANCER IMMUNOLOGY. The "cancer immunogram".

Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation.

Subtle CXCR3-Dependent Chemotaxis of CTLs within Infected Tissue Allows Efficient Target Localization.

Tumor-infiltrating lymphocytes for the treatment of metastatic cancer.

Translating Pembrolizumab to Clinical Practice: Speak Immunology and Learn Fast!

Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma.

Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor.

Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma.

Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts.

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.

Evolving synergistic combinations of targeted immunotherapies to combat cancer.

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Antigen design enhances the immunogenicity of Semliki Forest virus-based therapeutic human papillomavirus vaccines.

Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.

Toxicity patterns with immunomodulating antibodies and their combinations.

Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression.

NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy.

High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma.

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.

T cell memory. Skin-resident memory CD8⁺ T cells trigger a state of tissue-wide pathogen alert.

Manufacture of gene-modified human T-cells with a memory stem/central memory phenotype.

Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.

Acquired and intrinsic resistance in cancer immunotherapy.

Immune-escape markers in relation to clinical outcome of advanced melanoma patients following immunotherapy.

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.

Intradermal vaccination by DNA tattooing.

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.

Do targeted agents offer clinical benefit as presurgical therapy?

Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma.

The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand-foot syndrome.

Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma.

High-throughput identification of antigen-specific TCRs by TCR gene capture.

Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O).

Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20).

Immunotherapy of melanoma.

Transposon leads to contamination of clinical pDNA vaccine.

Vemurafenib as neoadjuvant treatment for unresectable regional metastatic melanoma.

Is combination therapy the next step to overcome resistance and reduce toxicities in melanoma?

Recent advances towards the clinical application of DNA vaccines.

Rational design of DNA vaccines for the induction of human papillomavirus type 16 E6- and E7-specific cytotoxic T-cell responses.

Tissue-resident memory CD8+ T cells continuously patrol skin epithelia to quickly recognize local antigen.

TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients.

Behavior and function of tissue-resident memory T cells.

Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission.

Tilting the AXIS towards therapeutic limits in renal cancer.

[Issues around melanoma].

This site uses cookies